News

The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent regulatory news surrounding CGM devices in the US and Europe.

Headed to ACC.22 this weekend or following along virtually? Hear from Don't Miss a Beat co-hosts Drs. Vaduganathan and Greene on their top picks from the late-breaking sessions at the upcoming American College of Cardiology meeting.

Nearly all of the doctors polled recommended the pneumococcal vaccine for patients with cardiovascular disease aged 65 years and older.

Investigators conducted the largest study on SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.

Dr. Bailey highlights the innovative nature of the procedure and breaks down the process at his institution.

The resolution of excess central retinal thickness in response to anti-VEGF therapy and the treatment burden were additionally similar between the 2 groups.

Human milk oligosaccharides could help treat some of the gut disruptions patients with depression often have.

Fecal microbiota transplantation is known to cure up to 88% of patients with recurrent C difficile infections.

Bristol Myers Squibb has to wait 3 months for FDA decision on Reblozyl for treating non-transfusion-dependent β-thalassemia.

In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors.

A new AAD study shows board-certified experts produce only one-fourth of the most popular TikTok posts on subjects in their field.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.

The VALIANT study featured a cross-sectional online survey that was used to recruit adult patients 18 years and older who were professionally diagnosed with vitiligo.

Data from the ADhere studies found that lebrikizumab was well tolerated in patients with atopic dermatitis.

A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.

The lens is added to a patient’s eye through a quick surgical procedure with no removal of corneal tissue and can be removed by a doctor if desired.

Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.

New AAD 2022 data support the novel gel therapy as the potentially first treatment for the viral-borne skin condition.

The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.

Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.

A new AAD 2022 study shows disparities in patch testing for allergens—and how certain fragrances, metals and preservations discriminately affect rates of contact dermatitis.

The ALLEGRO study detailed the efficacy and safety of ritlecitinib in adult and adolescent patients with the alopecia areata.

The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.

New phase 2 data from the KARE study presented at AAD found that the therapy improved itch severity and sleep in patients with atopic dermatitis and pruritis.

New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.

Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.